Recently, we encountered a bullish analysis on Pfizer Inc. on the Investing With Purpose Substack. This article aims to encapsulate the positive outlook on PFE shared by the authors. As of September 18th, shares of Pfizer Inc. were trading at $24.15, with trailing and forward P/E ratios of 12.78 and 7.74 respectively, according to Yahoo Finance.
M. A. Arkhipov/Shutterstock.com
Pfizer has undergone a sharp decline in revenue following the COVID pandemic, with sales expected to drop from around $100 billion in 2022 to approximately $58 billion in 2023. However, there is optimism with forecasts indicating a recovery to about $64 billion by 2025, spurred by new drug launches, particularly in oncology and treatments for rare diseases. Despite this revenue reduction, Pfizer continues to showcase strong profitability, achieving operating margins close to 28% and net margins surpassing 35%, largely due to disciplined expense management. The earnings per share (EPS) stands solid at roughly $2.20, resulting in a forward P/E ratio below 12x, significantly beneath the average for its industry.
The company generates upwards of $18 billion in annual free cash flow, which supports dividends, stock buybacks, and research and development without relying on external capital. Its balance sheet is solid, showcasing $60 billion in debt contrasted against $80 billion in equity and $15 billion in cash equivalents. With a dividend yield nearing 6.7%, Pfizer’s more substantial than historical norm is well supported by consistent cash flow generation, and notably, the company has not reduced its dividends since the 1940s. Should the yield revert to its historical average of about 4%, shares of Pfizer could imply a price range around $42 to $45, suggesting considerable upside potential.
Technical indicators align with a medium-term bullish outlook, exhibiting a higher-low and higher-high trend structure since May. With positive momentum illustrated by the RSI and MACD indicators, retracement support hovering around $25.10 to $25.20 offers a reasonable entry point for investors. Subsequent upside targets of $27.50 and $29 align with Fibonacci extensions, while a stop-loss situated below $24 would effectively guard against potential downside risk. In summary, Pfizer possesses a blend of defensive attributes, robust free cash flow, a re-rated valuation, and a promising pipeline of upcoming therapies, establishing itself as an appealing prospect for medium- to long-term investors who seek both sustainable income and possible capital appreciation.
In a previous analysis, we discussed a bullish thesis on Pfizer Inc. (PFE) articulated by Akim Guerreiro in September 2024, which underscored its high dividend yield, strong drug pipeline, strategic mergers and acquisitions including Seagen, and anticipated recovery in EBITDA and free cash flow. Despite a depreciation of roughly 17% in the stock since that coverage due to post-COVID revenue normalization, the underlying thesis remains relevant, given Pfizer’s steady cash flow, extensive pipeline, and attractive valuation. Investing With Purpose echoes this sentiment, albeit with an increased focus on detailed financial metrics and specific technical entry points.
This rewritten article retains the key points and HTML structure while providing fresh insights into Pfizer Inc.’s current situation and future prospects. It is designed to integrate smoothly within a WordPress platform.
